These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 35925889)
1. An anti-CTLA-4 heavy chain-only antibody with enhanced T Gan X; Shan Q; Li H; Janssens R; Shen Y; He Y; Chen F; van Haperen R; Drabek D; Li J; Zhang Y; Zhao J; Qin B; Jheng MJ; Chen V; Wang J; Rong Y; Grosveld F Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2200879119. PubMed ID: 35925889 [TBL] [Abstract][Full Text] [Related]
2. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691 [TBL] [Abstract][Full Text] [Related]
3. Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs. Guo C; Dai X; Du Y; Xiong X; Gui X Cancer Immunol Immunother; 2024 Aug; 73(10):210. PubMed ID: 39123089 [TBL] [Abstract][Full Text] [Related]
4. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582 [TBL] [Abstract][Full Text] [Related]
5. Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy. Sato Y; Casson CN; Matsuda A; Kim JI; Shi JQ; Iwasaki S; Chen S; Modrell B; Chan C; Tavares D; Austen D; Ida K; Tayber O; Hein P; Comeau R; Lin Y; Shaw MH Cancer Immunol Immunother; 2022 Oct; 71(10):2421-2431. PubMed ID: 35237846 [TBL] [Abstract][Full Text] [Related]
6. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies. Lax BM; Palmeri JR; Lutz EA; Sheen A; Stinson JA; Duhamel L; Santollani L; Kennedy A; Rothschilds AM; Spranger S; Sansom DM; Wittrup KD Proc Natl Acad Sci U S A; 2023 Aug; 120(31):e2300895120. PubMed ID: 37487077 [TBL] [Abstract][Full Text] [Related]
7. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826 [No Abstract] [Full Text] [Related]
8. FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Knorr DA; Blanchard L; Leidner RS; Jensen SM; Meng R; Jones A; Ballesteros-Merino C; Bell RB; Baez M; Marino A; Sprott D; Bifulco CB; Piening B; Dahan R; Osorio JC; Fox BA; Ravetch JV Cancer Immunol Res; 2024 Mar; 12(3):322-333. PubMed ID: 38147316 [TBL] [Abstract][Full Text] [Related]
9. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control. Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316 [TBL] [Abstract][Full Text] [Related]
10. Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice. Du X; Liu M; Su J; Zhang P; Tang F; Ye P; Devenport M; Wang X; Zhang Y; Liu Y; Zheng P Cell Res; 2018 Apr; 28(4):433-447. PubMed ID: 29463898 [TBL] [Abstract][Full Text] [Related]
12. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991 [TBL] [Abstract][Full Text] [Related]
13. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. Kvarnhammar AM; Veitonmäki N; Hägerbrand K; Dahlman A; Smith KE; Fritzell S; von Schantz L; Thagesson M; Werchau D; Smedenfors K; Johansson M; Rosén A; Åberg I; Winnerstam M; Nyblom E; Barchan K; Furebring C; Norlén P; Ellmark P J Immunother Cancer; 2019 Apr; 7(1):103. PubMed ID: 30975201 [TBL] [Abstract][Full Text] [Related]
14. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886 [TBL] [Abstract][Full Text] [Related]
15. Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade? Tang F; Du X; Liu M; Zheng P; Liu Y Cell Biosci; 2018; 8():30. PubMed ID: 29713453 [TBL] [Abstract][Full Text] [Related]
16. Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies. Zhang P; Xiong X; Rolfo C; Du X; Zhang Y; Yang H; Russo A; Devenport M; Zhou P; Liu Y; Zheng P Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31991588 [TBL] [Abstract][Full Text] [Related]